Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease

Recent analyses of autopsied brains from subjects previously administered AAV2-neurturin (NRTN) gene transfer argues that optimizing the effects of neurotrophic factors in Parkinson's disease (PD) likely requires delivery to both the degenerating cell bodies (in substantia nigra) and their term...

Full description

Bibliographic Details
Main Authors: Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jr., Jeffrey H. Kordower, Christopher D. Herzog
Format: Article
Language:English
Published: Elsevier 2011-10-01
Series:Neurobiology of Disease
Subjects:
Neurotrophic factors
Neurturin
Parkinson's disease
Translational research
Gene therapy
Gene transfer
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996111001987

Similar Items

Similar Items